New York, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Nexavar (sorafenib) - Drug Insight and Market Forecast - 2030" - https://www.reportlinker.com/p05865976/?utm_source=GNW
A detailed picture of the Nexavar (sorafenib) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2017–2030 is provided in this report along with a detailed description of the product. The product details covers mechanism of action, dosage and administration, route of synthesis, and pharmacological studies, including product marketed details, regulatory milestones, and other development activities. Further, it also consists of market assessments inclusive of the market forecast, SWOT analysis, and detailed analyst views. It further highlights the market competitors, late-stage emerging therapies, and patent details in the global space.

Nexavar is indicated for the treatment of patients with unresectable hepatocellular carcinoma (HCC). Sorafenib is a kinase inhibitor that decreases tumor cell proliferation in vitro. Sorafenib was shown to inhibit multiple intracellular (c-CRAF, BRAF and mutant BRAF) and cell surface kinases (KIT, FLT- 3, RET, RET/PTC, VEGFR-1, VEGFR- 2, VEGFR- 3, and PDGFR-•). Several of these kinases are thought to be involved in tumor cell signaling, angiogenesis and apoptosis. Sorafenib inhibited tumor growth of HCC, RCC, and DTC human tumor xenografts in immunocompromised mice. Reductions in tumor angiogenesis were seen in models of HCC and RCC upon sorafenib treatment, and increases in tumor apoptosis were observed in models of HCC, RCC, and DTC. Sorafenib is the first approved systemic therapy for liver cancer and the only one shown to significantly improve overall survival in patients with the disease. In 2005, sorafenib became the first new treatment in more than a decade for advanced kidney cancer, and is currently approved in more than 60 countries for this indication. On November 2013, orphan designation (EU/3/13/1200) was granted by the European Commission to Bayer HealthCare AG, Germany, for sorafenib tosylate for the treatment of papillary thyroid cancer. In May 2014, the sponsor changed name to Bayer Pharma AG.

Scope of the report
The report provides insights into:
• A comprehensive product overview including the product description, mechanism of action, dosage and administration, route of synthesis, pharmacological studies (pharmacodynamics and pharmacokinetics) and adverse reactions.
• Elaborated details on regulatory milestones and other development activities have been provided in this report.
• The report also highlights the drug marketed details across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around Nexavar (sorafenib).
• The report contains historical and forecasted sales for Nexavar (sorafenib) till 2030.
• Comprehensive coverage of the late-stage emerging therapies (Phase III) in the space with a brief snapshot of the details.
• The report also features the SWOT analysis with analyst insights and key findings of Nexavar (sorafenib).

Methodology
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis ’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
Nexavar (sorafenib) Analytical Perspective
• In-depth Nexavar (sorafenib) Market Assessment
This report provides a detailed market assessment of Nexavar (sorafenib) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides historical and forecasted sales data from 2017 to 2030.

• Nexavar (sorafenib) Clinical Assessment
The report provides the clinical trials information of Nexavar (sorafenib) covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights
• In the coming years, the market scenario for Nexavar (sorafenib) is set to change due to the extensive research in the treatment of the indicated condition and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence Nexavar (sorafenib) dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Other approved products for the disease are giving market competition to Nexavar (sorafenib) and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, development activities, and some key findings provide the current market scenario of Nexavar (sorafenib).
• Our in-depth analysis of the sales data of Nexavar (sorafenib) from 2017 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Nexavar (sorafenib) in the market.

Key Questions
• What is the prescribed dosage and strengths of Nexavar (sorafenib) are available in the market?
• What are the common adverse reactions or side effects of Nexavar (sorafenib)?
• What is the product type, route of administration and mechanism of action of Nexavar (sorafenib)?
• What are the chemical specifications of Nexavar (sorafenib)?
• How are the clinical trials diversified on the basis of the trial status?
• What is the history of Nexavar (sorafenib), and what is its future?
• What are the marketed details of Nexavar (sorafenib) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• How many patents have been granted to Nexavar (sorafenib) and when these patents will get expire?
• What are the pros (benefits) and cons (disadvantages) of Nexavar (sorafenib)?
• In which countries Nexavar (sorafenib) got approval and when it gets launched?
• What are the clinical trials are currently ongoing for Nexavar (sorafenib)?
• How the safety and efficacy results determined the approval of Nexavar (sorafenib)?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Nexavar (sorafenib) development?
• What are the key designations that have been granted to Nexavar (sorafenib)?
• What is the historical and forecasted market scenario of Nexavar (sorafenib)?
• How is the market trend of Nexavar (sorafenib) is different in the Seven Major Markets (the United States, EU5 [Germany, France, Italy, Spain, and the United Kingdom], and Japan)?
• What are the other approved products available and how these are giving competition to Nexavar (sorafenib)?
• Which are the late-stage emerging therapies under development for the treatment of the indicated condition?
Read the full report: https://www.reportlinker.com/p05865976/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001